期刊文献+

TNF-α单抗分子大小变异体与电荷变异体色谱行为的比较研究 被引量:2

Comparative study of size and charge heterogeneities of anti-TNF-αantibodies by high performance liquid chromatography
原文传递
导出
摘要 目的:分析对比原研TNF-α全人源单克隆抗体(单抗)和4个生物类似药的分子大小和电荷异质性差异。方法采用体积排阻色谱(SEC-HPLC)分析抗体大小异质性,采用弱阳离子交换色谱(WCX-HPLC)分析单抗电荷异质性。结合羧肽酶B(CpB)处理单抗,分析单抗主要电荷异质性来源。结果经体积排阻色谱检测发现,4个生物类似药与原研单抗在单体比例上基本一致,其中两个生物类似药(SBP-3,SBP-4)聚合物比例较原研单抗略高。离子交换色谱检测结果显示,4个生物类似药与原研单抗的电荷分布在碱区以及主峰比例上有明显差异。羧肽酶B处理样品后,样品碱区峰比例明显减少,提示4个生物类似药在碱区上的差异主要由C末端赖氨酸引起。结论4个生物类似药虽然在单抗分子大小异质性上与原研单抗无明显差别,然而在电荷变异体组成上却存在较大差异。在对单抗质量控制中应重视电荷异质性检测的重要性。 Objective To analyze the differences of size and charge heterogeneities between origi-nal humanized anti-TNF-αantibody and four similar biotherapeutic products ( SBP ) .Methods The size exclusion chromatography ( SEC-HPLC ) and weak cation exchange chromatography ( WCX-HPLC ) were used to analyze the size and charge heterogeneities , respectively.Carboxypeptidase B (CpB) treatment was employed to analyze the source of charge heterogeneity of the antibody products .Results Four SBPs showed the same pattern with the originator in SEC-HPLC, and no significant difference with the percentage of mono-mer was observed .The percentages of the aggregates of SBP-3 and SBP-4 were a little higher than those of the originator .The charge distribution of SBPs was significantly different from the originator ′s, especially in the basic region .The results from the samples treated with CpB indicated that the difference of charge distri -bution in the basic region might be caused by the C-terminal lysine variants .Conclusion Four SBPs showed similar size heterogeneity with the originator , but significant differences with charge heterogeneity were observed among them .The study suggested that more attention should be paid to the charge heterogene -ity analysis of the biosimilar products .
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2014年第9期723-726,共4页 Chinese Journal of Microbiology and Immunology
关键词 单克隆抗体 电荷异质性 大小异质性 Monoclonal antibody Size heterogeneity Charge heterogeneity
  • 相关文献

参考文献5

  • 1Sliwkowski MX, Mellman I. Antibody therapeutics in cancer[ J ]. Science, 2013, 341(6151 ): 1192-1198.
  • 2Gao K, Wang J. The biopharmaceutical industry in China: history and future perspectives [ J ]. Front Med, 2012, 6 (2) : 101-111.
  • 3Michels DA, Parker M, Salas-Solano O. Quantitative impurity analysis of monoclonal antibody size heterogeneity by CE-LIF: example of development and validation through a quality-by-design framework[ J]. Electrophoresis, 2012, 33 (5) : 815-826.
  • 4Rustandi RR, Washabaugh MW, Wang Y. Applications of CE SDS gel in development of biopharmaceutical antibody-based prod- ucts [ J ]. Electrophoresis, 2008, 29 ( 17 ) : 3612 -3620.
  • 5于传飞,李萌,郭玮,王兰,张峰,刘春雨,王文波,王军志,高凯.一种抗体药物偶联物中药物抗体偶联比的测定[J].药学学报,2014,49(3):363-367. 被引量:10

二级参考文献10

  • 1Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy [J]. Annu Rev Med, 2013, 64: 15-29.
  • 2Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxie payloads to cancer cells [J]. Ther Deliv, 2011, 2: 397-416.
  • 3Govindan SV, Goldenberg DM. New antibody conjugates in cancer therapy [J]. Sci World J, 2010, 10: 2070-2089.
  • 4Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer [J]. Curr Opin Chem Biol, 2010, 14: 529-537.
  • 5Teicher BA. Antibody-drug conjugate targets [J]. Curt Cancer Drug Targets, 2009, 9:982-1004.
  • 6Pasquetto MV, Vecchia L, Covini D, et al. Targeted drug delivery using immunoconjugates: principles and applications [J]. J Immunother, 2011, 34: 611-628.
  • 7Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs [J]. Cancer Res, 1992, 52: 127-131.
  • 8Wakankar A, Chen Y, Gokam Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates [J]. MAbs, 2011, 3: 161-172.
  • 9Wang L, Amphlett G, Blattler WA, et al. Structural charac- terization of the maytansinoid-monoclonal antibody immuno- conjugate, huN901-DM1, by massspectrometry [J]. Protein Sci, 2005, 14: 2436-46.
  • 10孙玉,于菲,孙柏旺.靶向癌症治疗试剂——抗体-药物偶联物(英文)[J].药学学报,2009,44(9):943-952. 被引量:10

共引文献9

同被引文献6

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部